New Treatment Regimens, New Drugs, and New Treatment Goals for Lupus Nephritis.

J Clin Med · 2025 · PMC11765719 · PMID 39860589

Europe PMC DOI

hedged sentence

0.1150

closest p · 2.3× alpha

0.1150

boldest claim

The sentences

did not reach statistical significancep = 0.115not close (p > 0.1)

At week 52, 35% of patients in the obinutuzumab group achieved CRR compared to 23% in the placebo group, although this difference did not reach statistical significance at that time (percentage difference: 12%, 95% CI: −3.4% to 28%, ( p = 0.115)).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.